The stock of Stemline Therapeutics Inc (NASDAQ:STML) is a huge mover today! About 137,472 shares traded hands. Stemline Therapeutics Inc (NASDAQ:STML) has risen 130.77% since April 13, 2016 and is uptrending. It has outperformed by 126.84% the S&P500.
The move comes after 7 months negative chart setup for the $234.50M company. It was reported on Nov, 15 by Barchart.com. We have $10.71 PT which if reached, will make NASDAQ:STML worth $23.45M less.
According to Zacks Investment Research, “Stemline Therapeutics, Inc. is a biopharmaceutical company developing oncology therapeutics that target cancer stem cells and tumor bulk. The company is developing SL-401, a biologic-drug conjugate, for relapsed or refractory acute myeloid leukemia; and SL-701, a synthetic peptide vaccine, for pediatric and adult high-grade gliomas. Stemline Therapeutics, Inc. is based in New York.”
Insitutional Activity: The institutional sentiment increased to 1.08 in 2016 Q2. Its up 0.12, from 0.96 in 2016Q1. The ratio improved, as 9 funds sold all Stemline Therapeutics Inc shares owned while 15 reduced positions. 8 funds bought stakes while 18 increased positions. They now own 9.63 million shares or 1.71% less from 9.80 million shares in 2016Q1.
Dimensional Fund Limited Partnership reported 34,337 shares or 0% of all its holdings. Franklin owns 2.10 million shares or 0.01% of their US portfolio. Art Advisors Lc last reported 12,061 shares in the company. The New York-based Blackrock has invested 0% in Stemline Therapeutics Inc (NASDAQ:STML). Blackrock Fund Advsrs holds 0% or 438,016 shares in its portfolio. Moreover, Rhumbline Advisers has 0% invested in Stemline Therapeutics Inc (NASDAQ:STML) for 26,260 shares. Moreover, Tiaa Cref Investment Mngmt Limited Liability Corporation has 0% invested in Stemline Therapeutics Inc (NASDAQ:STML) for 64,450 shares. Paradigm Asset Mgmt Communication Limited Liability Company holds 0% of its portfolio in Stemline Therapeutics Inc (NASDAQ:STML) for 20,800 shares. Bnp Paribas Arbitrage Sa has invested 0% of its portfolio in Stemline Therapeutics Inc (NASDAQ:STML). Blackrock Institutional Trust Na accumulated 187,428 shares or 0% of the stock. Vanguard Group owns 526,691 shares or 0% of their US portfolio. Baker Bros Advisors L P last reported 0.02% of its portfolio in the stock. Deutsche Comml Bank Ag has invested 0% of its portfolio in Stemline Therapeutics Inc (NASDAQ:STML). Citigroup has 0% invested in the company for 237 shares. Ny State Common Retirement Fund has 0% invested in the company for 31,200 shares.
Another recent and important Stemline Therapeutics Inc (NASDAQ:STML) news was published by Marketwatch.com which published an article titled: “Virtual Stock Exchange” on August 22, 2012.
STML Company Profile
Stemline Therapeutics, Inc., incorporated on August 8, 2003, is a clinical-stage biopharmaceutical firm focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Firm is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers. SL-701 is an immunotherapy designed to activate the immune system to attack tumors. SL-801 is an oral, small molecule that reversibly inhibits Exportin-1 (XPO1), also known as Chromosome Region Maintenance-1 (CRM-1), a nuclear transport protein.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.